New targeted drug shows promise for Hard-to-Treat gynecologic cancers
NCT ID NCT07311538
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called BRY812 in people with advanced ovarian, endometrial, or ovarian clear cell cancers that have a specific marker (LIV-1). The goal is to see if the drug can shrink tumors and how safe it is. About 56 participants will receive the drug, and researchers will monitor their response and any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GYNECOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Can a smart drug missile take down a tough ovarian cancer?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Scientists probe hidden clues to immunotherapy success in endometrial cancer
- New drug combo aims to stall endometrial cancer